Goldman Sachs’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-722,369
| Closed | -$82K | – | 5627 |
|
|
2018
Q4 | $82K | Buy |
722,369
+30,890
| +4% | +$20.3K | ﹤0.01% | 5032 |
|
|
2018
Q3 | $1.18M | Sell |
691,479
-82,516
| -11% | -$148K | ﹤0.01% | 3947 |
|
|
2018
Q2 | $1.35M | Sell |
773,995
-786,152
| -50% | -$1.36M | ﹤0.01% | 3881 |
|
|
2018
Q1 | $2.85M | Sell |
1,560,147
-465,932
| -23% | -$984K | ﹤0.01% | 3324 |
|
|
2017
Q4 | $4.52M | Sell |
2,026,079
-1,291,591
| -39% | -$3.21M | ﹤0.01% | 3090 |
|
|
2017
Q3 | $9.62M | Buy |
3,317,670
+1,109,945
| +50% | +$3.79M | ﹤0.01% | 2582 |
|
|
2017
Q2 | $9.82M | Buy |
2,207,725
+782,648
| +55% | +$3.23M | ﹤0.01% | 2521 |
|
|
2017
Q1 | $6.64M | Buy |
1,425,077
+411,699
| +41% | +$2.39M | ﹤0.01% | 2700 |
|
|
2016
Q4 | $6.17M | Buy |
1,013,378
+360,831
| +55% | +$1.89M | ﹤0.01% | 2869 |
|
|
2016
Q3 | $3.6M | Buy |
652,547
+121,412
| +23% | +$568K | ﹤0.01% | 3331 |
|
|
2016
Q2 | $2.02M | Sell |
531,135
-25,493
| -5% | -$86.4K | ﹤0.01% | 3616 |
|
|
2016
Q1 | $1.54M | Buy |
556,628
+220,145
| +65% | +$797K | ﹤0.01% | 3719 |
|
|
2015
Q4 | $1.91M | Buy |
336,483
+174,745
| +108% | +$1.07M | ﹤0.01% | 3677 |
|
|
2015
Q3 | $857K | Buy |
161,738
+21,024
| +15% | +$163K | ﹤0.01% | 4623 |
|
|
2015
Q2 | $1.17M | Buy |
140,714
+10,872
| +8% | +$52.7K | ﹤0.01% | 4401 |
|
|
2015
Q1 | $600K | Sell |
129,842
-16,364
| -11% | -$53.2K | ﹤0.01% | 4953 |
|
|
2014
Q4 | $446K | Sell |
146,206
-18,599
| -11% | -$55K | ﹤0.01% | 5389 |
|
|
2014
Q3 | $459K | Buy |
164,805
+111,328
| +208% | +$404K | ﹤0.01% | 5357 |
|
|
2014
Q2 | $218K | Sell |
53,477
-10,558
| -16% | -$44.9K | ﹤0.01% | 6138 |
|
|
2014
Q1 | $340K | Buy |
64,035
+8,874
| +16% | +$49.7K | ﹤0.01% | 5628 |
|
|
2013
Q4 | $306K | Buy |
55,161
+36,801
| +200% | +$159K | ﹤0.01% | 5682 |
|
|
2013
Q3 | $83K | Buy |
18,360
+3,521
| +24% | +$15.8K | ﹤0.01% | 6209 |
|
|
2013
Q2 | $63K | Buy |
+14,839
| New | +$74.6K | ﹤0.01% | 5998 |
|
Other funds holding SGYP
Goldman Sachs's SGYP Position: Q1 2019 in Review
Goldman Sachs sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 722,369 shares — an estimated $82K sold.
Goldman Sachs first reported a position in SGYP in Q2 2013 and held it in 23 quarters. The position peaked at $9.82M in Q2 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.
- Goldman Sachs reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
- Goldman Sachs sold 722,369 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $82K.
- Goldman Sachs first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 23 quarters.
- Goldman Sachs's Synergy Pharmaceuticals, Inc Common Stock position peaked at $9.82M in Q2 2017.
- 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.
Based on Goldman Sachs's 13F filing for Q1 2019, filed 15 May 2019.